Newsroom

Sorted by: Latest

-

Willdan Group Reports First Quarter Results

ANAHEIM, Calif.--(BUSINESS WIRE)--Willdan Group, Inc. (“Willdan”) (Nasdaq: WLDN) today announced its financial results for the first quarter ended April 3, 2026. The first quarter of fiscal 2026 had one fewer week than the first quarter of fiscal 2025, thus normalized results are also presented. First Quarter 2026 Highlightsa Contract revenue of $155.1 million, up 1.8% (up 9.6% normalized). Net revenueb of $92.4 million, up 8.3% (up 16.6% normalized). Net income of $8.5 million, up 82.0% (up 96...
-

CoreWeave Reports Strong First Quarter 2026 Results

LIVINGSTON, N.J.--(BUSINESS WIRE)--CoreWeave Reports Strong First Quarter 2026 Earnings...
-

HASI Announces Executive Appointments

ANNAPOLIS, Md.--(BUSINESS WIRE)--HA Sustainable Infrastructure Capital, Inc. (“HASI,” “we” or “our”) (NYSE: HASI) today announced executive appointments, effective May 12, 2026. “I am pleased to announce these management changes and promotions as we continue to recruit and retain top talent to drive our ongoing success,” said Jeffrey A. Lipson, President and Chief Executive Officer of HASI. “All of these individuals are accomplished executives with a collaborative approach, and I am extremely c...
-

Nu Skin Enterprises Reports First Quarter Results

PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)%   • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges Customers 669,535; (14)% Paid Affiliates 120,850; (8)% Sales Leaders 26,915; (13)% “We del...
-

Curbline Properties Declares Common Stock Dividend of $0.17 for Second Quarter 2026

NEW YORK--(BUSINESS WIRE)--Curbline Properties Corp. (NYSE: CURB), an owner of convenience centers in suburban, high household income communities, declared today a second quarter 2026 dividend on its common stock of $0.17 per share. The dividend is payable on July 9, 2026 to stockholders of record at the close of business on June 18, 2026. About Curbline Properties Curbline Properties is an owner and manager of convenience shopping centers positioned on the curbline of well-trafficked intersect...
-

Toast Announces First Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Toast Announces First Quarter 2026 Financial Results...
-

Jamieson Wellness Inc. Reports First Quarter 2026 Results

TORONTO--(BUSINESS WIRE)--Jamieson Wellness Inc. (“Jamieson Wellness” or the “Company”) (TSX: JWEL) today reported its first quarter results for the period ended March 31, 2026. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See “Non-IFRS and Other Financial Measures” below. Management Commentary “Q1 marked a strong start to the year, underscoring the effectiveness of our strategy and our...
-

SITE Centers Reports First Quarter 2026 Results

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Reports First Quarter 2026 Results...
-

Covista Third Quarter Fiscal Year 2026 Results; Raises Fiscal Year 2026 Revenue and Adjusted Earnings Per Share Guidance

CHICAGO--(BUSINESS WIRE)--Covista Inc. (NYSE: CVSA), the largest healthcare educator in the United States, today reported third quarter fiscal year 2026 results (ended Mar. 31, 2026). The Company continues to execute on its Growth with Purpose strategy, leading the transformation of higher education by training the next generation of healthcare professionals at an industry-leading scale. “The country needs more nurses, physicians, and behavioral health professionals than the current system is o...
-

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for...